Vertaling van "combat counterfeit medicines and " (Nederlands → Frans) :

De Raad van Europa organiseert verschillende sessies “Working across disciplines and borders – best practices to combat counterfeit medicines and to protect public health” waarbij 3 deelnemers per land worden uitgenodigd.
Le Conseil de l’Europe organise différentes sessions Working across disciplines and borders – best practices to combat counterfeit medicines and to protect public health, auxquelles sont invités trois participants par pays.

Interpol keurde in oktober 2008 8 eveneens een resolutie “Improving international co-operation to combat counterfeit medical products” goed waarbij de landen worden aangespoord om in samenwerking met alle betrokken partners zoals bijvoorbeeld geneesmiddelenagentschappen meer informatie uit te wisselen.
Interpol a par ailleurs approuvé, en octobre 2008 8 , une résolution (Improving international co-operation to combat counterfeit medical products) encourageant les pays à intensifier l’échange d’informations en collaboration avec tous les partenaires concernés, comme par exemple les agences de médicaments.

Hier worden actuele onderwerpen aangepakt (informatie-uitwisseling, trendanalyse enz.) zoals de enforcement problemen binnen de geneesmiddelendistributie, het internet, de problemen rond grondstoffen, namaakgeneesmiddelen en de training van enforcement officers met betrekking tot farmaceutische criminaliteit Sinds 2003 neemt de FAGG ook een sturende rol waar binnen de “Ad Hoc Workgroup Counterfeit Medicines “ in de Raad van Europa in Straatsburg.
Cette organisation se penche sur des problèmes d’actualité (échange d’informations, analyse de tendances…) tels que les problèmes liés à la répression des infractions dans le cadre de la distribution des médicaments, l’internet, les problèmes liés aux matières premières, les médicaments contrefaits et l’entraînement des enforcement officers en matière de criminalité pharmaceutique. Depuis 2003, l’AFMPS joue également un rôle directeur au sein de l’Ad Hoc Group on Counterfeit Medicines du Conseil de l’Europe à Strasbourg.

Finally, in 2008 the Special Investigation Unit (SOE-USE) started its work. This unit is charged with combating pharmaceutical crime and is of extreme importance given the significant increase in the number of cases of counterfeits.
Finally, in 2008 the Special Investigation Unit (SOE-USE) started its work. This unit is charged with combating pharmaceutical crime and is of extreme importance given the significant increase in the number of cases of counterfeits.

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Finally, in recent years a troubling phenomenon has been on the rise: the counterfeiting of medicines and health products.
Finally, in recent years a troubling phenomenon has been on the rise: the counterfeiting of medicines and health products.

The NITD works with local and international researchers – as well as Novartis research centers – to develop medicines to combat rapidly spreading conditions such as dengue fever, malaria and tuberculosis.
Il collabore avec des chercheurs locaux et internationaux – de même qu’avec d’autres centres de recherche Novartis – pour développer des médicaments contre les maladies qui se propagent rapidement, comme la dengue, la malaria ou la tuberculose.

“This effort builds on the ongoing work of many partners committed to improving the lives of the 1 billion people affected by NTDs, most of whom are among the world’s poorest. “At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.
“At Pfizer, we are working to combat NTDs by collaborating on drug development, broadening access to medicines and strengthening health care delivery for underserved people.

The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.
The Production & Distribution department of the FAMHP is responsible firstly for overseeing the conformity to current standards, guidelines and legal requirements for the manufacture, distribution and dispensing of medicines and health products and secondly for granting authorisations, recognitions and certificates, as well as for combating illegal practices and monitoring pharmacies.